|
1.
Share Success: Letters From Readers
Letter I: From William G.
Received
at sharesuccess @ ezorbonline.com Tuesday, May 28, 2019, 1:29 PM PDT
(Unedited)
One of the best calcium's I have every taken, my bones are stronger, my nails stopped breaking and I don't have to take medicine for osteoporosis anymore. Three cheers for that.
Sent from Yahoo Mail for iPad
Letter II: From Helen, Canada
Received
at Testimonial Submit Form Saturday, April 27, 2019 at 06:19:59
(Unedited)
Hi, my name is Helen. I live in Canada and am 68 years young.
I am taking 6 of the EZorb calcium and 4 of the Marvlix per day for bone spurs. I have 3 more days of the first bottles. It is so nice to no longer have pain in my fingers from arthritis.
I realize the bone spurs I've had for years will take longer, but at least I know the
products are working.
I also do not need to go to the chiropractor as often. I am hoping over time they will also help with 2 areas in my back that have degenerative disc issues.
I would like to take the recommended dosage to start, but because of the cost with a minimum of 30% exchange on the dollar I can only afford to take the maintenance dosage.
My main concern about this or any product was kidney stones. I've suffered the pain 4 times in my life and did not want to go through a 5th, so their advertising that this does not cause stones was another reason for me to order.
I am looking forward to better health as I continue to take the next 2 of the 3 bottles I first ordered. I will be ordering more. Thank you to all those that worked so hard to formulate and get this product to market.
***************************************************
From
the Desk of EZorb Newsletter Editor:
This
newsletter is now read by over 120,000 subscribers
worldwide. Success stories you have contributed over
the years have had a great impact on many people's
quality of life. Your continuous support will be
greatly appreciated by tens of thousands who have been
suffering and would continuously suffer, without your
help! Please email your
story to sharesuccess @ ezorbonline.com
or simply post it at Testimonial
Submit Form. Your personal information will never be
revealed to the public. We appreciate your effort.
2.
Research News: Diabetes Care Ethnic Disparities Reported
Researchers have revealed significant disparities in the monitoring and treatment of type 2 diabetes across England, with Black and Asian patients and those living in the most deprived areas at a particular disadvantage.
Routinely collected information from 49,380 patients at 164 primary care centers who were diagnosed with type 2 diabetes before 2012 and followed up over a 5-year period revealed ethnic and socioeconomic differences in glycemic control, healthcare monitoring, and the prescription of newer drugs such as sodium-glucose cotransporter (SGLT)2 inhibitors and glucagon-like peptide (GLP)-1 agonists.
Compared with White individuals, those who were Black (4.1%) were half as likely to be prescribed SGLT2 inhibitors and 55% less likely to receive GLP-1 agonists during the study period from 2012 to 2016, while for Asian patients (9.0%) these figures were a corresponding 32% and 63%.
Asian patients were also a significant 14% less likely than their White counterparts to be prescribed insulin, according to the data collected through the Royal College of General Practitioners Research and Surveillance Center database. Overall, the mean age of the participants was 68.7 years at the end of the study, and mean BMI was 30.7 kg/m2.
Both Black and Asian patients had significantly worse glycemic control than White patients and their most recently measured glycated hemoglobin (HbA1c) levels were greater by 2.36 and 1.10 mmol/mol, respectively.
When patients were divided into fifths according to where they lived, those in the most deprived group had a significant 1.86 mmol/mol higher HbA1c level, on average, at the most recent measure than those in the highest socioeconomic group.
Those in the top socioeconomic fifth were additionally more likely than others to receive healthcare monitoring, in the form of annual testing for HbA1c, estimated glomerular filtration rate (eGFR), blood pressure, neuropathy, and retinopathy.
Black patients were significantly less likely than White individuals to have uninterrupted annual monitoring for HbA1c or retinopathy, at 11% and 18%, respectively.
Patients from an Asian background were significantly more likely than White participants to have unbroken annual HbA1c and eGFR monitoring, at 10% and 9%, respectively, but 12% less likely to have complete retinopathy or neuropathy screening.
"Our data support the 'inverse equity' hypothesis whereby preventative services are accessed first by the rich and well-informed, there is then an initial widening of the inequality gap before it later narrows," write Martin Whyte (University of Surrey, Guildford, UK) and co-workers in PLOS Medicine.
They conclude that more research is needed to determine whether the disparities observed "represent inequality in care."
Original article was published in PLOS Med 2019; 16: e1002942.
3.
Useful Links
Frequently
Asked Questions & Answers
EZorb
Clinical Studies
Marvlix
Benefits
Order
Now
4.
Calcium
Absorption Test
EZorb
Calcium has set a new world record of absorption rate.
You can compare EZorb with other calcium supplements
by using the simple step-by-step instructions we
provide. E-mail your request to test @ elixirindustry.com
for a copy of the instructions.
5.
What Are Others Saying About EZorb and Marvlix?
EZorb and Marvlix have restored confidence in thousands of men
and women. It has brought happiness and healthy life
to families around the world. Click here
to read what people say about EZorb and Marvlix. |
